| Otsuka Pharmaceutical (Switzerland) GmbH - Jinarc 45 mg + 15 mg, Tabletten | | 65676 | | 03 | | Jinarc 45 mg + 15 mg | | Tabletten | | C03XA01 | | Tolvaptan | | 21.04.2016 | | |
| | Composition | | A): tolvaptanum 45 mg, hydroxypropylcellulosum, lactosum monohydricum 12.629 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, E 132 pro compresso.
B): tolvaptanum 15 mg, hydroxypropylcellulosum, lactosum monohydricum 36.913 mg, maydis amylum, cellulosum microcristallinum, hydroxypropylcellulosum substitutum humile, magnesii stearas, E 132 pro compresso. | | Packungsbestandteile | | A | | | Comprimés | | | | | Principe actif | Concentr. |
|---|
| Tolvaptanum | 45 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Tolvaptanum | 15 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| Cellulosum Microcristallinum | | | | E 132 | | color. | | Hydroxypropylcellulosum | | | | Hydroxypropylcellulosum Substitutum Humile | | | | Lactose Monohydrate | 12.629 mg | | | Magnesii Stearas | | | | Maydis Amylum | | | | Pro Compresso | | |
| |
| B | | | Comprimés | | | | | Principe actif | Concentr. |
|---|
| Tolvaptanum | 15 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Tolvaptanum | 15 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| Cellulosum Microcristallinum | | | | E 132 | | color. | | Hydroxypropylcellulosum | | | | Hydroxypropylcellulosum Substitutum Humile | | | | Lactose Monohydrate | 36.913 mg | | | Magnesii Stearas | | | | Maydis Amylum | | | | Pro Compresso | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 006 | 28 + 28 | 1288.92 | 1418.20 | A | LS | Oui |
|
|
